Table 1

Univariate analysis of the prognostic impact of 9 biomarkers on OS (endpoint) in the learning set (AML SHG 0199 trial)

BiomarkerHR95% CIP*IPRS weight
Age ≥ 40 y vs < 40 y 3.6 1.97-6.65 < .001 3 
NPM1/FLT3 mutation status: high vs low-risk† 1.9 1.15-3.06 .012 2 
CEBPA nonmutated vs CEBPA mutated 2.4 1.13-5.26 .010 2 
WT1 SNP rs16754: homozygous for major allele vs ≥ 1 minor allele‡ 2.3 1.34-4.08 .003 2 
BAALC expression: high vs low 1.9 1.23-2.92 .004 2 
WBC count: ≥ 25 × 109/L vs < 25 × 109/L 1.6 1.03-2.38 .035 1 
MN1 expression: high vs low 1.6 1.03-2.37 .037 1 
ERG expression: high vs low 1.6 1.06-2.46 .027 1 
WT1 expression: high vs low 1.6 1.05-2.46 .030 1 
BiomarkerHR95% CIP*IPRS weight
Age ≥ 40 y vs < 40 y 3.6 1.97-6.65 < .001 3 
NPM1/FLT3 mutation status: high vs low-risk† 1.9 1.15-3.06 .012 2 
CEBPA nonmutated vs CEBPA mutated 2.4 1.13-5.26 .010 2 
WT1 SNP rs16754: homozygous for major allele vs ≥ 1 minor allele‡ 2.3 1.34-4.08 .003 2 
BAALC expression: high vs low 1.9 1.23-2.92 .004 2 
WBC count: ≥ 25 × 109/L vs < 25 × 109/L 1.6 1.03-2.38 .035 1 
MN1 expression: high vs low 1.6 1.03-2.37 .037 1 
ERG expression: high vs low 1.6 1.06-2.46 .027 1 
WT1 expression: high vs low 1.6 1.05-2.46 .030 1 

Hazard ratios > 1 or < 1 indicate an increased or decreased risk, respectively, of an event for the first category listed. IPRS weights are as follows: low risk, 1-7 points; intermediate risk, 8-10 points; and high risk, 11-15 points.

WBC indicates white blood cell count.

*

Two-sided from univariate Cox proportional hazard model.

†

The high-risk molecular group is defined as NPM1wildtype/FLT3-ITD−, NPM1wildtype/FLT3-ITD+, or NPM1mutated/FLT3-ITD+. The low-risk molecular group is defined by the absence of FLT3-ITD and by the simultaneous presence of an NPM1 mutation.

‡

The WT1 polymorphism rs16754 is defined as ≥ 1 minor allele (WT1AG or GG) and homozygous for the major allele (WT1AA).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal